Shandong LINUO Pharmaceutical Co., Ltd
As of 20 November 2026, for the company name Shandong LINUO Pharmaceutical Co., Ltd as recorded, 2 applications with this name as first applicant are listed as under review at China's CDE; the CDE acceptance records name it as first applicant on 21 records, across 13 drug names; since 23 August 2026, the records list Accepted: 2 applications (NMPA data as of 19 November 2026); the chemical-drug catalogue lists 15 active records with this name as holder.
Check drug filings and source records for this company-name string.
Listed by the company name as recorded in the source, without merging affiliated entities.
Page reference
These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/20.
Drug filings
21 acceptance records as first applicant, grouped into 13 source drug names. Source data as of 2026/11/20.
Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.
Dapagliflozin Tablets 2 records · Latest accepted 2026/11/11
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2602047 | Supplement | 2026/11/11 | Shandong LINUO Pharmaceutical Co., Ltd; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
| CYHB2602046 | Supplement | 2026/11/11 | Shandong LINUO Pharmaceutical Co., Ltd; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
Betahistine Dihydrochloride Tablets 3 records · Latest accepted 2026/07/10
Supplement · 3
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2601320 | Supplement | 2026/07/10 | Shandong LINUO Pharmaceutical Co., Ltd; Jinan Yong Ning Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2601319 | Supplement | 2026/07/10 | Shandong LINUO Pharmaceutical Co., Ltd; Jinan Yong Ning Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2601215 | Supplement | 2026/06/29 | Shandong LINUO Pharmaceutical Co., Ltd; Jinan Yong Ning Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Febuxostat Tablets 2 records · Latest accepted 2025/09/24
Supplement · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2501886 | Supplement | 2025/09/24 | Shandong LINUO Pharmaceutical Co., Ltd; Qingdao Bai Yang Pharmaceutical Co., Ltd. romanized | CDE ↗ |
| CYHB2501885 | Supplement | 2025/09/24 | Shandong LINUO Pharmaceutical Co., Ltd; Qingdao Bai Yang Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Isavuconazonium Sulfate for Injection 1 records · Latest accepted 2025/03/18
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2500549 | Supplement | 2025/03/18 | Shandong LINUO Pharmaceutical Co., Ltd; Shanxi De Yuan Tang Pharma Co., Ltd. romanized | CDE ↗ |
Metformin Hydrochloride And Empagliflozin Extended Release Tablets 2 records · Latest accepted 2024/12/17
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2404373 | Generic | 2024/12/17 | Shandong LINUO Pharmaceutical Co., Ltd; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
| CYHS2404372 | Generic | 2024/12/17 | Shandong LINUO Pharmaceutical Co., Ltd; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
Isosorbide Dinitrate Injection 2 records · Latest accepted 2024/10/24
Generic · 2
Esmolol Hydrochloride Injection 1 records · Latest accepted 2024/10/12
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2403395 | Generic | 2024/10/12 | Shandong LINUO Pharmaceutical Co., Ltd; Shandong Fang Ming Pharma Group Co., Ltd. romanized | CDE ↗ |
Piracetam Injection 2 records · Latest accepted 2024/10/10
Generic · 2
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2403348 | Generic | 2024/10/10 | Shandong LINUO Pharmaceutical Co., Ltd; Shandong Fang Ming Pharma Group Co., Ltd. romanized | CDE ↗ |
| CYHS2403347 | Generic | 2024/10/10 | Shandong LINUO Pharmaceutical Co., Ltd; Shandong Fang Ming Pharma Group Co., Ltd. romanized | CDE ↗ |
Lurasidone Hydrochloride Tablets 1 records · Latest accepted 2024/07/23
Generic · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHS2402309 | Generic | 2024/07/23 | Shandong LINUO Pharmaceutical Co., Ltd | CDE ↗ |
Calcium Dobesilate Capsules 1 records · Latest accepted 2024/05/15
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2400655 | Supplement | 2024/05/15 | Shandong LINUO Pharmaceutical Co., Ltd; Hainan Lin Heng Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Piracetam Tablets 2 records · Latest accepted 2024/01/18
Supplement · 2
Metformin Hydrochloride Extended-release Tablets 1 records · Latest accepted 2023/10/21
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2302346 | Supplement | 2023/10/21 | Shandong LINUO Pharmaceutical Co., Ltd; Gai Tian Li Pharmaceuticals Holding Group Pharmaceutical Co., Ltd. romanized | CDE ↗ |
Isosorbide Mononitrate Extended-Release Tablets 1 records · Latest accepted 2021/10/26
Supplement · 1
| Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|
| CYHB2150940 | Supplement | 2021/10/26 | Shandong LINUO Pharmaceutical Co., Ltd | CDE ↗ |
Changes in the last 90 days
2 events from 2026/08/23 to 2026/11/20. CDE data as of 2026/11/20; NMPA data as of 2026/11/19.
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Accepted: 2 applications
- 2026/11/11Accepted
Dapagliflozin Tablets
CYHB2602047
Fact date: 2026/11/11 · Date added to this site: 2026/11/12
View source ↗ - 2026/11/11Accepted
Dapagliflozin Tablets
CYHB2602046
Fact date: 2026/11/11 · Date added to this site: 2026/11/12
View source ↗
Under review
2 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| Dapagliflozin Tablets | CYHB2602047 | Supplement | 2026/11/11 | Shandong LINUO Pharmaceutical Co., Ltd; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
| Dapagliflozin Tablets | CYHB2602046 | Supplement | 2026/11/11 | Shandong LINUO Pharmaceutical Co., Ltd; Chongqing Bo Teng Pharma Co., Ltd. romanized | CDE ↗ |
Catalogue holder records
15 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/20. Manufacturer-only records are excluded.
| Drug | Marketing authorization holder | Manufacturer | NMPA approval no. | Approved | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 恩格列净二甲双胍缓释片(IV) · No verified English name | Shandong LINUO Pharmaceutical Co., Ltd | Chongqing Bo Teng Pharma Co., Ltd. romanized | 国药准字H20265844 | 2026/09/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| 恩格列净二甲双胍缓释片(III) · No verified English name | Shandong LINUO Pharmaceutical Co., Ltd | Chongqing Bo Teng Pharma Co., Ltd. romanized | 国药准字H20265843 | 2026/09/02 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Esmolol Hydrochloride Injection | Shandong LINUO Pharmaceutical Co., Ltd | Shandong Fang Ming Pharma Group Co., Ltd. romanized | 国药准字H20265279 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Isosorbide Dinitrate Injection | Shandong LINUO Pharmaceutical Co., Ltd | Zhongfu Pharmaceutical Co., Ltd. | 国药准字H20265281 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Isosorbide Dinitrate Injection | Shandong LINUO Pharmaceutical Co., Ltd | Zhongfu Pharmaceutical Co., Ltd. | 国药准字H20265280 | 2026/07/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Piracetam Injection | Shandong LINUO Pharmaceutical Co., Ltd | Shandong Fang Ming Pharma Group Co., Ltd. romanized | 国药准字H20264088 | 2026/04/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Piracetam Injection | Shandong LINUO Pharmaceutical Co., Ltd | Shandong Fang Ming Pharma Group Co., Ltd. romanized | 国药准字H20264087 | 2026/04/21 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Lurasidone Hydrochloride Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H20263162 | 2026/01/20 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Isavuconazonium Sulfate for Injection | Shandong LINUO Pharmaceutical Co., Ltd | Shanxi De Yuan Tang Pharma Co., Ltd. romanized | 国药准字H20254537 | 2025/06/17 | Generic approved under the new chemical-drug registration classification | CDE ↗ |
| Piracetam Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H37023561 | 2024/11/19 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Piracetam Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H37023561 | 2024/11/19 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Isosorbide Mononitrate Extended-Release Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H19991115 | 2022/10/14 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| Fluoxetine Hydrochloride Dispersible Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H20123161 | 2021/12/07 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| IsosorbideMononitrate Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H10940255 | 2021/10/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
| IsosorbideMononitrate Tablets | Shandong LINUO Pharmaceutical Co., Ltd | Shandong LINUO Pharmaceutical Co., Ltd | 国药准字H10940140 | 2021/10/27 | Drug that passed quality-and-efficacy consistency evaluation | CDE ↗ |
Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.
API registrations
0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/20.
| Name | Company / applicant | Registration number | Status | Source update date | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.
Co-applicant records
0 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/20.
| Drug | Acceptance number | Application type | Accepted | Company / applicant | View source |
|---|---|---|---|---|---|
| No matching records were found in the currently loaded source data; coverage dates are listed below. | |||||
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/20
- Chemical-drug catalogue
- Last successful update: 2026/11/20
- API registrations
- Last successful update: 2026/11/20
- NMPA drug delivery notices
- Last successful update: 2026/11/19
Loaded notices dated 2026-11-05 to 2026-11-19; 0 notices not yet loaded. Covers loaded notices only, not a complete historical approval database.
Listed by the company name as recorded in the source, without merging affiliated entities.
This page summarizes loaded records only. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.
Fact dates are approval dates, acceptance dates, trial first-publication dates, or the date an application stopped being listed as under review. Publication dates and dates added to this site are listed separately. Historical records with earlier dates are not current-period new events. Exit records cover currently inactive applications whose delisting date is known, not a full review history.
Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.
Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.